BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu PH, Hsu CY, Hsia CY, Lee YH, Su CW, Huang YH, Lee FY, Lin HC, Huo TI. Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol. 2016;64:601-608. [PMID: 26551516 DOI: 10.1016/j.jhep.2015.10.029] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 16.4] [Reference Citation Analysis]
Number Citing Articles
1 Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, Huang YH, Lei HJ, He YJ, Hou MC, Huo TI. An Albumin-Bilirubin (ALBI) Grade-based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria. Am J Clin Oncol. 2019;42:698-704. [PMID: 31335351 DOI: 10.1097/coc.0000000000000581] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
2 Ho SY, Liu PH, Hsu CY, Hsia CY, Su CW, Lee YH, Huang YH, Lee FY, Hou MC, Huo TI. Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Sci Rep. 2018;8:4773. [PMID: 29555927 DOI: 10.1038/s41598-018-22923-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
3 Shen J, He L, Li C, Wen T, Chen W, Lu C, Yan L, Li B, Yang J. Nomograms to Predict the Individual Survival of Patients with Solitary Hepatocellular Carcinoma after Hepatectomy. Gut Liver 2017;11:684-92. [PMID: 28651303 DOI: 10.5009/gnl16465] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
4 Chen J, Cao J, Wang P, He X. NT5DC2 is a novel prognostic marker in human hepatocellular carcinoma. Oncol Lett 2020;20:70. [PMID: 32863903 DOI: 10.3892/ol.2020.11931] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Zhang ZQ, Xiong L, Zhou JJ, Miao XY, Li QL, Wen Y, Zou H. Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC. World J Surg Oncol. 2018;16:208. [PMID: 30326907 DOI: 10.1186/s12957-018-1500-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
6 Yan WT, Quan B, Yu JJ, Yang T. Should we invariably follow the current guidelines to treat our HCC patients? Hepatobiliary Pancreat Dis Int 2019;18:301-2. [PMID: 30686653 DOI: 10.1016/j.hbpd.2019.01.005] [Reference Citation Analysis]
7 Borzio M, Dionigi E, Rossini A, Marignani M, Sacco R, De Sio I, Bertolini E, Francica G, Giacomin A, Parisi G, Vicari S, Toldi A, Salmi A, Boccia S, Mitra M, Fornari F. External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study. Hepatology 2018;67:2215-25. [PMID: 29165831 DOI: 10.1002/hep.29662] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
8 Su TH, Liao SH, Hong CM, Liu CJ, Tseng TC, Liu CH, Yang HC, Chen PJ, Chen DS, Chen CL, Adhoute X, Bourlière M, Kao JH. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. J Gastroenterol Hepatol 2019;34:2179-86. [PMID: 31062879 DOI: 10.1111/jgh.14705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Chen P, Chiu N, Su C, Huang Y, Hou M, Lin H, Wu J. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. Journal of the Chinese Medical Association 2019;82:2-10. [DOI: 10.1097/jcma.0000000000000001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
11 Zhang H, Qiu C, Zeng H, Zhu W, Lyu W, Lao X. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma. Genet Test Mol Biomarkers 2021;25:504-14. [PMID: 34280005 DOI: 10.1089/gtmb.2020.0093] [Reference Citation Analysis]
12 Xu Q, Lin W, Tao C, Huang X, Li J. Chondroitin polymerizing factor (CHPF) contributes to malignant proliferation and migration of hepatocellular carcinoma cells. Biochem Cell Biol 2020;98:362-9. [PMID: 32383983 DOI: 10.1139/bcb-2019-0227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Ho SY, Liu PH, Hsu CY, Ko CC, Huang YH, Su CW, Hsia CY, Lee RC, Hou MC, Huo TI. ALBI grade in dialysis patients with hepatocellular carcinoma: prognostic impact and staging strategy. J Gastrointest Oncol 2021;12:722-34. [PMID: 34012661 DOI: 10.21037/jgo-20-332] [Reference Citation Analysis]
14 Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. World J Gastroenterol 2017; 23(14): 2545-2555 [PMID: 28465639 DOI: 10.3748/wjg.v23.i14.2545] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
15 Rui T, Zhang X, Feng S, Huang H, Zhan S, Xie H, Zhou L, Ling Q, Zheng S. The Similar Effects of miR-512-3p and miR-519a-2-5p on the Promotion of Hepatocellular Carcinoma: Different Tunes Sung With Equal Skill. Front Oncol 2020;10:1244. [PMID: 32850377 DOI: 10.3389/fonc.2020.01244] [Reference Citation Analysis]
16 Zheng BH, Liu LZ, Zhang ZZ, Shi JY, Dong LQ, Tian LY, Ding ZB, Ji Y, Rao SX, Zhou J, Fan J, Wang XY, Gao Q. Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients. BMC Cancer. 2018;18:1148. [PMID: 30463529 DOI: 10.1186/s12885-018-5024-z] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis]
17 Deng X, Bi Q, Chen S, Chen X, Li S, Zhong Z, Guo W, Li X, Deng Y, Yang Y. Identification of a Five-Autophagy-Related-lncRNA Signature as a Novel Prognostic Biomarker for Hepatocellular Carcinoma. Front Mol Biosci 2020;7:611626. [PMID: 33505990 DOI: 10.3389/fmolb.2020.611626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Xin H, Liang D, Zhang M, Ren D, Chen H, Zhang H, Li S, Ding G, Zhang C, Ding Z, Wu L, Han W, Zhou W, Chen Y, Luo H, Wang Y, Zhang H, Liu S, Li N. The CD68+ macrophages to CD8+ T-cell ratio is associated with clinical outcomes in hepatitis B virus (HBV)-related hepatocellular carcinoma. HPB (Oxford) 2021;23:1061-71. [PMID: 33309570 DOI: 10.1016/j.hpb.2020.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Kim YH, Jeong DC, Pak K, Han ME, Kim JY, Liangwen L, Kim HJ, Kim TW, Kim TH, Hyun DW, Oh SO. SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma. Oncotarget 2017;8:68381-92. [PMID: 28978124 DOI: 10.18632/oncotarget.20266] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
20 Ho SY, Liu PH, Hsu CY, Huang YH, Liao JI, Su CW, Hou MC, Huo TI. A New Tumor Burden Score and Albumin-Bilirubin Grade-Based Prognostic Model for Hepatocellular Carcinoma. Cancers (Basel) 2022;14:649. [PMID: 35158917 DOI: 10.3390/cancers14030649] [Reference Citation Analysis]
21 Trojan J, Zangos S, Schnitzbauer AA. Diagnostics and Treatment of Hepatocellular Carcinoma in 2016: Standards and Developments. Visc Med. 2016;32:116-120. [PMID: 27413729 DOI: 10.1159/000445730] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
22 Kawaguchi T, Tokushige K, Hyogo H, Aikata H, Nakajima T, Ono M, Kawanaka M, Sawada K, Imajo K, Honda K, Takahashi H, Mori K, Tanaka S, Seko Y, Nozaki Y, Kamada Y, Fujii H, Kawaguchi A, Takehara T, Yanase M, Sumida Y, Eguchi Y, Seike M, Yoneda M, Suzuki Y, Saibara T, Karino Y, Chayama K, Hashimoto E, George J, Torimura T. A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. Sci Rep. 2018;8:10434. [PMID: 29992975 DOI: 10.1038/s41598-018-28650-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
23 Jeng LB, Li TC, Hsu SC, Chan WL, Teng CF. Association of Low Serum Albumin Level with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection. J Clin Med 2021;10:4187. [PMID: 34575311 DOI: 10.3390/jcm10184187] [Reference Citation Analysis]
24 Zhu Z, Zhang Y, Huang C, Tang Y, Sun C, Ju W, He X. Overexpression of RALY promotes migration and predicts poor prognosis in hepatocellular carcinoma. Cancer Manag Res 2018;10:5559-72. [PMID: 30519104 DOI: 10.2147/CMAR.S182996] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Yang D, Wu H, Nong W, Zheng M, Li A, Wang Y, Li M, Chen Q, Yuan S, Yu J, Liao W. A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021;45:101509. [PMID: 33744828 DOI: 10.1016/j.clinre.2020.07.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Li W, Xu L, Han J, Yuan K, Wu H. Identification and Validation of Tumor Stromal Immunotype in Patients With Hepatocellular Carcinoma. Front Oncol 2019;9:664. [PMID: 31448222 DOI: 10.3389/fonc.2019.00664] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
27 Teng CF, Li TC, Huang HY, Chan WL, Wu HC, Shyu WC, Su IJ, Jeng LB. Hepatitis B virus pre-S2 deletion (nucleotide 1 to 54) in plasma predicts recurrence of hepatocellular carcinoma after curative surgical resection. PLoS One 2020;15:e0242748. [PMID: 33237972 DOI: 10.1371/journal.pone.0242748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 Zhu J, Tang B, Gao Y, Xu S, Tu J, Wang Y, Yang W, Fang S, Weng Q, Zhao Z, Xu M, Yang Y, Chen M, Lu C, Ji J. Predictive Models for HCC Prognosis, Recurrence Risk, and Immune Infiltration Based on Two Exosomal Genes: MYL6B and THOC2. J Inflamm Res 2021;14:4089-109. [PMID: 34466015 DOI: 10.2147/JIR.S315957] [Reference Citation Analysis]
29 Heinrich S, Sprinzl M, Schmidtmann I, Heil E, Koch S, Czauderna C, Heinrich B, Philippe P Diggs L, Wörns MA, Kloeckner R, Galle PR, Marquardt JU, Weinmann A. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. United European Gastroenterol J 2020;8:444-52. [PMID: 32213028 DOI: 10.1177/2050640620904524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Morris JS, Hassan M, Amin H, Kaseb A. REPLY. Hepatology 2021;73:2612. [PMID: 33170975 DOI: 10.1002/hep.31620] [Reference Citation Analysis]
31 Yu B, Liang H, Ye Q, Wang Y. Upregulation of ERCC6L is associated with tumor progression and unfavorable prognosis in hepatocellular carcinoma. J Gastrointest Oncol 2020;11:1009-23. [PMID: 33209494 DOI: 10.21037/jgo-20-192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
32 Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM. Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol. 2017;27:4472-4481. [PMID: 28439654 DOI: 10.1007/s00330-017-4844-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
33 Chen LJ, Chang YJ, Chang YJ. Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma. Oncologist 2021;26:e445-53. [PMID: 32969134 DOI: 10.1002/onco.13535] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Liao M, Chen P, Liao Y, Li J, Yao W, Sun T, Liao W, Su L. Preoperative high-sensitivity C-reactive protein to lymphocyte ratio index plays a vital role in the prognosis of hepatocellular carcinoma after surgical resection. Onco Targets Ther 2018;11:5591-600. [PMID: 30237725 DOI: 10.2147/OTT.S167857] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Chen X, Liao Y, Yu Y, Zhu P, Li J, Qin L, Liao W, Huang Z. Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma. Oncotarget 2017;8:92589-603. [PMID: 29190940 DOI: 10.18632/oncotarget.21506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
36 Liao R, Peng C, Li M, Li DW, Jiang N, Li PZ, Ding X, Wu Q, Du CY, Gong JP. Comparison and validation of the prognostic value of preoperative systemic immune cells in hepatocellular carcinoma after curative hepatectomy. Cancer Med 2018;7:1170-82. [PMID: 29533004 DOI: 10.1002/cam4.1424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
37 Cho SH, Pak K, Jeong DC, Han M, Oh S, Kim YH. The AP2M1 gene expression is a promising biomarker for predicting survival of patients with hepatocellular carcinoma. J Cell Biochem 2019;120:4140-6. [DOI: 10.1002/jcb.27699] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
38 Gan W, Zhang MX, Wang JX, Fu YP, Huang JL, Yi Y, Jing CY, Fan J, Zhou J, Qiu SJ. Prognostic impact of lactic dehydrogenase to albumin ratio in hepatocellular carcinoma patients with Child-Pugh I who underwent curative resection: a prognostic nomogram study. Cancer Manag Res 2018;10:5383-94. [PMID: 30464634 DOI: 10.2147/CMAR.S176317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
39 Papaconstantinou D, Hewitt DB, Brown ZJ, Schizas D, Tsilimigras DI, Pawlik TM. Patient stratification in hepatocellular carcinoma: impact on choice of therapy. Expert Rev Anticancer Ther 2022. [PMID: 35157530 DOI: 10.1080/14737140.2022.2041415] [Reference Citation Analysis]
40 Teng CF, Li TC, Wang T, Liao DC, Wen YH, Wu TH, Wang J, Wu HC, Shyu WC, Su IJ, Jeng LB. Increased infiltration of regulatory T cells in hepatocellular carcinoma of patients with hepatitis B virus pre-S2 mutant. Sci Rep 2021;11:1136. [PMID: 33441885 DOI: 10.1038/s41598-020-80935-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Huo TI, Ho SY, Liu PH. Selecting an optimal prognostic model for advanced hepatocellular carcinoma: Any new ideas? Dig Liver Dis 2021;53:1208-9. [PMID: 34011481 DOI: 10.1016/j.dld.2021.04.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Zheng X, Wang P, Li L, Yu J, Yu C, Xu L, Li L, Dai F, Feng L, Zou H, Chen X, Zhang M, Xu M. Cancer-Associated Fibroblasts Promote Vascular Invasion of Hepatocellular Carcinoma via Downregulating Decorin-integrin β1 Signaling. Front Cell Dev Biol 2021;9:678670. [PMID: 34504839 DOI: 10.3389/fcell.2021.678670] [Reference Citation Analysis]
43 Fu Y, Wei X, Han Q, Le J, Ma Y, Lin X, Xu Y, Liu N, Wang X, Kong X, Gu J, Tong Y, Wu H. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma. BMC Cancer 2021;21:1165. [PMID: 34717566 DOI: 10.1186/s12885-021-08827-z] [Reference Citation Analysis]
44 Marasco G, Trevisani F; Italian Liver Cancer (ITA.LI.CA.) group. Time to move beyond the classical prognostic systems for patients with advanced hepatocellular carcinoma undergoing Sorafenib. Dig Liver Dis 2021;53:1210-1. [PMID: 34052178 DOI: 10.1016/j.dld.2021.04.037] [Reference Citation Analysis]
45 Liu ZK, Wu KF, Zhang RY, Kong LM, Shang RZ, Lv JJ, Li C, Lu M, Yong YL, Zhang C, Zheng NS, Li YH, Chen ZN, Bian H, Wei D. Pyroptosis-Related LncRNA Signature Predicts Prognosis and Is Associated With Immune Infiltration in Hepatocellular Carcinoma. Front Oncol 2022;12:794034. [PMID: 35311105 DOI: 10.3389/fonc.2022.794034] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Duan JL, Nie RC, Xiang ZC, Chen JW, Deng MH, Liang H, Wang FW, Luo RZ, Xie D, Cai MY. Prognostic Model for the Risk Stratification of Early and Late Recurrence in Hepatitis B Virus-Related Small Hepatocellular Carcinoma Patients with Global Histone Modifications. J Hepatocell Carcinoma 2021;8:493-505. [PMID: 34095004 DOI: 10.2147/JHC.S309451] [Reference Citation Analysis]
47 Shen J, Tang L, Zhang X, Peng W, Wen T, Li C, Yang J, Liu G. A Novel Index in Hepatocellular Carcinoma Patients After Curative Hepatectomy: Albumin to Gamma-Glutamyltransferase Ratio (AGR). Front Oncol 2019;9:817. [PMID: 31612101 DOI: 10.3389/fonc.2019.00817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
48 Lai Y, Wang X, Zeng T, Xing S, Dai S, Wang J, Chen S, Li X, Xie Y, Zhu Y, Liu W. Serum VEGF levels in the early diagnosis and severity assessment of non-small cell lung cancer. J Cancer 2018;9:1538-47. [PMID: 29760791 DOI: 10.7150/jca.23973] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
49 Lhewa D, Green EW, Naugler WE. Multidisciplinary Team Management of Hepatocellular Carcinoma Is Standard of Care. Clin Liver Dis. 2020;24:771-787. [PMID: 33012458 DOI: 10.1016/j.cld.2020.07.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Sun P, Chen S, Li Y. The association between pretreatment serum alkaline phosphatase and prognosis in hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2020;99:e19438. [PMID: 32176073 DOI: 10.1097/MD.0000000000019438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Choo SP, Tan WL, Goh BKP, Tai WM, Zhu AX. Comparison of hepatocellular carcinoma in Eastern versus Western populations. Cancer. 2016;122:3430-3446. [PMID: 27622302 DOI: 10.1002/cncr.30237] [Cited by in Crossref: 106] [Cited by in F6Publishing: 109] [Article Influence: 17.7] [Reference Citation Analysis]
52 Liao R, Li D, Du C, Li M. Combined Preoperative ALBI and FIB-4 Is Associated with Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. J Gastrointest Surg 2018;22:1679-87. [DOI: 10.1007/s11605-018-3810-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
53 Sherman M. Staging for hepatocellular carcinoma: An embarrassment of riches. J Hepatol 2016;64:535-6. [PMID: 26682728 DOI: 10.1016/j.jhep.2015.11.040] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
54 Wang Z, Fan Q, Wang M, Wang E, Li H, Liu L. Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma. Ann Transl Med 2020;8:537. [PMID: 32411760 DOI: 10.21037/atm.2020.02.114] [Reference Citation Analysis]
55 Wallace MC, Huang Y, Preen DB, Garas G, Adams LA, MacQuillan G, Tibballs J, Ferguson J, Samuelson S, Jeffrey GP. HKLC Triages More Hepatocellular Carcinoma Patients to Curative Therapies Compared to BCLC and Is Associated with Better Survival. Dig Dis Sci. 2017;62:2182-2192. [PMID: 28547649 DOI: 10.1007/s10620-017-4622-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
56 Aishanjiang K, Wei XD, Fu Y, Lin X, Ma Y, Le J, Han Q, Wang X, Kong X, Gu J, Wu H. Circular RNAs and Hepatocellular Carcinoma: New Epigenetic Players With Diagnostic and Prognostic Roles. Front Oncol 2021;11:653717. [PMID: 33959506 DOI: 10.3389/fonc.2021.653717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Ji F, Fu SJ, Guo ZY, Pang H, Ju WQ, Wang DP, Hua YP, He XS. Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2016;95:e4065. [PMID: 27399091 DOI: 10.1097/MD.0000000000004065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
58 Raffetti E, Portolani N, Molfino S, Mentasti S, Baiocchi GL, Magoni M, Donato F. Is survival for hepatocellular carcinoma increasing? A population-based study on survival of hepatocellular carcinoma patients in the 1990s and 2000s. Clin Res Hepatol Gastroenterol 2021;45:101433. [PMID: 32409284 DOI: 10.1016/j.clinre.2020.04.004] [Reference Citation Analysis]
59 Hershberger CE, Rodarte AI, Siddiqi S, Moro A, Acevedo-Moreno LA, Brown JM, Allende DS, Aucejo F, Rotroff DM. Salivary Metabolites are Promising Non-Invasive Biomarkers of Hepatocellular Carcinoma and Chronic Liver Disease. Liver Cancer Int 2021;2:33-44. [PMID: 34541549 DOI: 10.1002/lci2.25] [Reference Citation Analysis]
60 Khalil A, Elfert A, Ghanem S, Helal M, Abdelsattar S, Elgedawy G, Obada M, Abdel-samiee M, El-said H. The role of metabolomics in hepatocellular carcinoma. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00085-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Ponziani FR, Spinelli I, Rinninella E, Cerrito L, Saviano A, Avolio AW, Basso M, Miele L, Riccardi L, Zocco MA, Annicchiarico BE, Garcovich M, Biolato M, Marrone G, De Gaetano AM, Iezzi R, Giuliante F, Vecchio FM, Agnes S, Addolorato G, Siciliano M, Rapaccini GL, Grieco A, Gasbarrini A, Pompili M. Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. World J Hepatol 2017; 9(36): 1322-1331 [PMID: 29359015 DOI: 10.4254/wjh.v9.i36.1322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
62 Lewin M, Laurent-Bellue A, Desterke C, Radu A, Feghali JA, Farah J, Agostini H, Nault JC, Vibert E, Guettier C. Evaluation of perfusion CT and dual-energy CT for predicting microvascular invasion of hepatocellular carcinoma. Abdom Radiol (NY) 2022;47:2115-27. [PMID: 35419748 DOI: 10.1007/s00261-022-03511-7] [Reference Citation Analysis]
63 Li J, Jin J, Liao M, Dang W, Chen X, Wu Y, Liao W. Upregulation of RECQL4 expression predicts poor prognosis in hepatocellular carcinoma. Oncol Lett 2018;15:4248-54. [PMID: 29541191 DOI: 10.3892/ol.2018.7860] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
64 Phan C, Zheng Z, Wang J, Wang Q, Hu X, Tang G, Bai H. Enhanced antitumour effect for hepatocellular carcinoma in the advanced stage using a cyclodextrin-sorafenib-chaperoned inclusion complex. Biomater Sci 2019;7:4758-68. [PMID: 31509117 DOI: 10.1039/c9bm01190k] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Shimizu T, Ishizuka M, Park KH, Shiraki T, Sakuraoka Y, Mori S, Iso Y, Kato M, Aoki T, Kubota K. Preoperative lymphocyte-to-monocyte ratio is useful for stratifying the prognosis of hepatocellular carcinoma patients with a low Cancer of the Liver Italian Program score undergoing curative resection. Ann Gastroenterol Surg 2019;3:325-35. [PMID: 31131362 DOI: 10.1002/ags3.12251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
66 Wu JY, Sun JX, Wu JY, Huang XX, Bai YN, Wei YG, Zhang ZB, Zhou JY, Cheng SQ, Yan ML. Impact of Bile Duct Tumor Thrombus on the Long-Term Surgical Outcomes of Hepatocellular Carcinoma Patients: A Propensity Score Matching Analysis. Ann Surg Oncol 2021. [PMID: 34591226 DOI: 10.1245/s10434-021-10799-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Ho SY, Liu PH, Hsu CY, Hsia CY, Huang YH, Su CW, Lei HJ, Lee RC, Hou MC, Huo TI. A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria. Dig Dis Sci. 2020;65:658-667. [PMID: 31659612 DOI: 10.1007/s10620-019-05813-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
68 Tellapuri S, Sutphin PD, Beg MS, Singal AG, Kalva SP. Staging systems of hepatocellular carcinoma: A review. Indian J Gastroenterol 2018;37:481-91. [DOI: 10.1007/s12664-018-0915-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
69 Bednarsch J, Czigany Z, Heise D, Joechle K, Luedde T, Heij L, Bruners P, Ulmer TF, Neumann UP, Lang SA. Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. Langenbecks Arch Surg. 2021;406:75-86. [PMID: 33294952 DOI: 10.1007/s00423-020-02052-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
70 Surveillance group. ; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381-403. [PMID: 29074347 DOI: 10.1016/j.jfma.2017.09.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
71 Dai W, Dai JL, Tang MH, Ye MS, Fang S. lncRNA-SNHG15 accelerates the development of hepatocellular carcinoma by targeting miR-490-3p/ histone deacetylase 2 axis. World J Gastroenterol 2019; 25(38): 5789-5799 [PMID: 31636472 DOI: 10.3748/wjg.v25.i38.5789] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
72 Li H, Wang L, Chen L, Zhao H, Cai J, Yao J, Zheng J, Yang Y, Wang G. Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio in Hepatocellular Carcinoma Patients Treated with Liver Transplantation. J Cancer 2020;11:2171-80. [PMID: 32127944 DOI: 10.7150/jca.39615] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
73 Tian M, Liu W, Tao C, Tang Z, Zhou Y, Song S, Jin L, Wang H, Jiang X, Zhou P, Fang Y, Qu W, Ding Z, Peng Y, Fu X, Qiu S, Zhou J, Fan J, Shi Y. Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: ISICC -applied prediction model. Cancer Sci 2020;111:1084-92. [PMID: 31971309 DOI: 10.1111/cas.14315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
74 Ho SY, Hsu CY, Liu PH, Hsia CY, Su CW, Huang YH, Hou MC, Huo TI. Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. Eur J Surg Oncol. 2019;45:776-781. [PMID: 30401507 DOI: 10.1016/j.ejso.2018.10.541] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
75 Huo TI, Liu PH, Hsu CY. Letter to the Editor: Using Circulating Biomarkers to Stage HCC: Pitfalls and Limitations. Hepatology 2021;73:2611. [PMID: 33170973 DOI: 10.1002/hep.31618] [Reference Citation Analysis]
76 Sadiq AM, Mashonganyika TJ, Mmbaga LG, Sadiq AM, Nkya GZ. Hepatocellular carcinoma in a non-cirrhotic liver with a tumor thrombus. Clin Case Rep 2021;9:e04800. [PMID: 34512986 DOI: 10.1002/ccr3.4800] [Reference Citation Analysis]
77 Hansmann J, Ray CE Jr. Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology. Semin Intervent Radiol 2017;34:213-9. [PMID: 28579689 DOI: 10.1055/s-0037-1602757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
78 Chen L, Song L, Shao Y, Li D, Ding K. Using natural language processing to extract clinically useful information from Chinese electronic medical records. Int J Med Inform 2019;124:6-12. [PMID: 30784428 DOI: 10.1016/j.ijmedinf.2019.01.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 6.7] [Reference Citation Analysis]
79 Chen WY, Diao YK, Jia HD, Liang L, Yang T. Association Between Olfactomedin 4 and Postoperative Prognosis in Patients With Early-Stage Hepatocellular Carcinoma. Clin Transl Gastroenterol 2020;11:e00163. [PMID: 32568478 DOI: 10.14309/ctg.0000000000000163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Zhu J, Tang B, Li J, Shi Y, Chen M, Lv X, Meng M, Weng Q, Zhang N, Fan K, Xu M, Ji J. Identification and validation of the angiogenic genes for constructing diagnostic, prognostic, and recurrence models for hepatocellular carcinoma. Aging (Albany NY) 2020;12:7848-73. [PMID: 32379058 DOI: 10.18632/aging.103107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
81 Fu S, Wei J, Zhang J, Dong D, Song J, Li Y, Duan C, Zhang S, Li X, Gu D, Chen X, Hao X, He X, Yan J, Liu Z, Tian J, Lu L. Selection Between Liver Resection Versus Transarterial Chemoembolization in Hepatocellular Carcinoma: A Multicenter Study. Clin Transl Gastroenterol. 2019;10:e00070. [PMID: 31373932 DOI: 10.14309/ctg.0000000000000070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
82 Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, Wu CY. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. JAMA Intern Med 2019;179:633-40. [PMID: 30882847 DOI: 10.1001/jamainternmed.2018.8342] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 23.5] [Reference Citation Analysis]
83 Shen X, Wang W, Niu X. Neutrophil Lymphocyte Ratio to Albumin Ratio and White Blood Cell to Hemoglobin Ratio as Prognostic Markers for Hepatocellular Carcinoma Patients Who Underwent Curative Hepatectomy. Int J Gen Med 2021;14:5029-38. [PMID: 34511986 DOI: 10.2147/IJGM.S329911] [Reference Citation Analysis]
84 D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68:563-576. [PMID: 29111320 DOI: 10.1016/j.jhep.2017.10.020] [Cited by in Crossref: 116] [Cited by in F6Publishing: 97] [Article Influence: 23.2] [Reference Citation Analysis]
85 Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Seminars in Diagnostic Pathology 2017;34:153-9. [DOI: 10.1053/j.semdp.2016.12.011] [Cited by in Crossref: 153] [Cited by in F6Publishing: 164] [Article Influence: 30.6] [Reference Citation Analysis]
86 Ho SY, Liu PH, Hsu CY, Ko CC, Huang YH, Su CW, Hsia CY, Tsai PH, Chou SJ, Lee RC, Hou MC, Huo TI. Easy albumin-bilirubin score as a new prognostic predictor in hepatocellular carcinoma. Hepatol Res 2021. [PMID: 34038019 DOI: 10.1111/hepr.13671] [Reference Citation Analysis]
87 Li J, Tao HS, Li J, Wang WQ, Sheng WW, Huang ZY, Zhang EL. Effect of Severity of Liver Cirrhosis on Surgical Outcomes of Hepatocellular Carcinoma After Liver Resection and Microwave Coagulation. Front Oncol 2021;11:745615. [PMID: 34692526 DOI: 10.3389/fonc.2021.745615] [Reference Citation Analysis]
88 Dong K, Liang B, Zhang Z, Zhang E, Yang G, Xia S, Chen X, Huang Z. Histologic severity of liver cirrhosis: A key factor affecting surgical outcomes of hepatocellular carcinoma in patients with portal hypertension. Asian Journal of Surgery 2019;42:981-9. [DOI: 10.1016/j.asjsur.2019.01.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
89 Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML, Toyoda H, Nguyen MH. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. Hepatology 2020;71:1910-22. [PMID: 31610027 DOI: 10.1002/hep.30988] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 18.5] [Reference Citation Analysis]
90 Adhoute X, Penaranda G, Raoul JL, Bourlière M. Hepatocellular carcinoma scoring and staging systems. Do we need new tools? J Hepatol. 2016;64:1449-1450. [PMID: 26912407 DOI: 10.1016/j.jhep.2016.01.038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
91 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
92 Vitale A, Farinati F, Pawlik TM, Frigo AC, Giannini EG, Napoli L, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, Cillo U. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. Liver Int 2019;39:1478-89. [PMID: 31131974 DOI: 10.1111/liv.14154] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
93 Trevisan França de Lima L, Broszczak D, Zhang X, Bridle K, Crawford D, Punyadeera C. The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer 2020;1874:188451. [PMID: 33065194 DOI: 10.1016/j.bbcan.2020.188451] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
94 Liao R, Du CY, Gong JP, Luo F. HBV-DNA Load-Related Peritumoral Inflammation and ALBI Scores Predict HBV Associated Hepatocellular Carcinoma Prognosis after Curative Resection. J Oncol 2018;2018:9289421. [PMID: 30327670 DOI: 10.1155/2018/9289421] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
95 Ferrell LD, Kakar S, Terracciano LM, Wee A. Tumours and Tumour-like Lesions of the Liver. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 780-879. [DOI: 10.1016/b978-0-7020-6697-9.00013-3] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
96 Ho SY, Liu PH, Hsu CY, Hsia CY, Lee YH, Lee RC, Huang YH, Lee FY, Hou MC, Tsai YJ, Huo TI. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One. 2017;12:e0180408. [PMID: 28672011 DOI: 10.1371/journal.pone.0180408] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
97 Wang ZX, Peng W, Zhang XY, Wen TF, Li C. Prognostic significance of postoperative change of PALBI grade for patients with hepatocellular carcinoma after hepatectomy. Medicine (Baltimore) 2021;100:e24476. [PMID: 33725934 DOI: 10.1097/MD.0000000000024476] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Xu L, Jian X, Liu Z, Zhao J, Zhang S, Lin Y, Xie L. Construction and Validation of an Immune Cell Signature Score to Evaluate Prognosis and Therapeutic Efficacy in Hepatocellular Carcinoma. Front Genet 2021;12:741226. [PMID: 34646307 DOI: 10.3389/fgene.2021.741226] [Reference Citation Analysis]
99 Guo Y, Chen L, Sun C, Yu C. MicroRNA-500a promotes migration and invasion in hepatocellular carcinoma by activating the Wnt/β-catenin signaling pathway. Biomed Pharmacother 2017;91:13-20. [PMID: 28437633 DOI: 10.1016/j.biopha.2017.04.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
100 Lange A, Muniraj T, Aslanian HR. Endoscopic Ultrasound for the Diagnosis and Staging of Liver Tumors. Gastrointest Endosc Clin N Am 2019;29:339-50. [PMID: 30846157 DOI: 10.1016/j.giec.2018.12.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
101 Liu PH, Huo TI. Reply to "Hepatocellular carcinoma scoring and staging systems. Do we need new tools?". J Hepatol 2016;64:1450-2. [PMID: 26912406 DOI: 10.1016/j.jhep.2016.02.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
102 Adhoute X, Penaranda G, Raoul JL, Le Treut P, Bollon E, Hardwigsen J, Castellani P, Perrier H, Bourlière M. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol 2016; 8(17): 703-715 [PMID: 27330679 DOI: 10.4254/wjh.v8.i17.703] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
103 Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomin A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA. LI.CA study group. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. PLoS Med. 2016;13:e1002006. [PMID: 27116206 DOI: 10.1371/journal.pmed.1002006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 10.7] [Reference Citation Analysis]
104 Wei L, Delin Z, Kefei Y, Hong W, Jiwei H, Yange Z. A classification based on tumor budding and immune score for patients with hepatocellular carcinoma. Oncoimmunology 2020;9:1672495. [PMID: 32002283 DOI: 10.1080/2162402X.2019.1672495] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
105 Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, Kudo M, Howell J, Ramaswami R, Burlone ME, Guerra V, Thimme R, Ishizuka M, Stebbing J, Pirisi M, Carr BI. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. Journal of Hepatology 2017;66:338-46. [DOI: 10.1016/j.jhep.2016.09.008] [Cited by in Crossref: 144] [Cited by in F6Publishing: 142] [Article Influence: 28.8] [Reference Citation Analysis]
106 Fu XW, Song CQ. Identification and Validation of Pyroptosis-Related Gene Signature to Predict Prognosis and Reveal Immune Infiltration in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:748039. [PMID: 34820376 DOI: 10.3389/fcell.2021.748039] [Reference Citation Analysis]
107 Liu X, Hou Y, Wang X, Yu L, Wang X, Jiang L, Yang Z. Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer. Hepatol Int 2020;14:567-76. [DOI: 10.1007/s12072-020-10046-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
108 Demir T, Lee SS, Kaseb AO. Systemic therapy of liver cancer. Adv Cancer Res 2021;149:257-94. [PMID: 33579425 DOI: 10.1016/bs.acr.2020.12.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
109 Wang K, Xiang YJ, Yu HM, Cheng YQ, Qin YY, Wang WJ, Zhang XP, Zheng YT, Shan YF, Cong WM, Dong H, Lau WY, Cheng SQ. A novel classification in predicting prognosis and guiding postoperative management after R0 liver resection for patients with hepatocellular carcinoma and microvascular invasion. Eur J Surg Oncol 2021:S0748-7983(21)01438-4. [PMID: 34996665 DOI: 10.1016/j.ejso.2021.12.466] [Reference Citation Analysis]
110 Mo Z, Cao Z, Luo S, Chen Y, Zhang S. Novel Molecular Subtypes Associated With 5mC Methylation and Their Role in Hepatocellular Carcinoma Immunotherapy. Front Mol Biosci 2020;7:562441. [PMID: 33195409 DOI: 10.3389/fmolb.2020.562441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
111 Rhee H, Cho E, Nahm JH, Jang M, Chung YE, Baek S, Lee S, Kim M, Park M, Han DH, Choi J, Park YN. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. Journal of Hepatology 2021;74:109-21. [DOI: 10.1016/j.jhep.2020.08.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
112 Xu Q, Hu Y, Chen S, Zhu Y, Li S, Shen F, Guo Y, Sun T, Chen X, Jiang J, Huang W. Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma. Front Mol Biosci 2021;8:683240. [PMID: 34124163 DOI: 10.3389/fmolb.2021.683240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
113 Chong CC, Chan AW, Wong J, Chu CM, Chan SL, Lee KF, Yu SC, To KF, Johnson P, Lai PB. Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma. Surgeon. 2018;16:163-170. [PMID: 28807570 DOI: 10.1016/j.surge.2017.07.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
114 Hu S, Gan W, Qiao L, Ye C, Wu D, Liao B, Yang X, Jiang X. A New Prognostic Algorithm Predicting HCC Recurrence in Patients With Barcelona Clinic Liver Cancer Stage B Who Received PA-TACE. Front Oncol 2021;11:742630. [PMID: 34745962 DOI: 10.3389/fonc.2021.742630] [Reference Citation Analysis]
115 Wang Q, Xia D, Bai W, Wang E, Han G. Reply to: "The "six-and-twelve score" for TACE treatment: Does it really help us?". J Hepatol 2019;71:1053-4. [PMID: 31500855 DOI: 10.1016/j.jhep.2019.07.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Wu H, Liu TT, Feng YM, Xie XY, Su XN, Qi JN, Zhu Q, Qin CY. Prognostic effect of a novel long noncoding RNA signature and comparison with clinical staging systems for patients with hepatitis B virus‐related hepatocellular carcinoma after hepatectomy. J Dig Dis 2020;21:650-63. [DOI: 10.1111/1751-2980.12941] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
117 Yamamoto M, Kobayashi T, Kuroda S, Hamaoka M, Okimoto S, Honmyo N, Yamaguchi M, Ohdan H. Verification of inflammation-based prognostic marker as a prognostic indicator in hepatocellular carcinoma. Ann Gastroenterol Surg 2019;3:667-75. [PMID: 31788655 DOI: 10.1002/ags3.12286] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
118 Ho SY, Hsu CY, Liu PH, Hsia CY, Lei HJ, Huang YH, Ko CC, Su CW, Lee RC, Hou MC, Huo TI. Albumin-bilirubin grade-based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. Liver Int. 2020;40:205-214. [PMID: 31505104 DOI: 10.1111/liv.14249] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
119 Edeline J, Blanc JF, Campillo-Gimenez B, Ma YT, King J, Faluyi O, Mathurin J, Ghazi S, Palmer DH, Meyer T. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. Eur J Cancer 2017;86:135-42. [PMID: 28987770 DOI: 10.1016/j.ejca.2017.08.036] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
120 Wu L, Bartlett A, Plank L, McCall J. Validation of the Hong Kong liver cancer staging system in hepatocellular carcinoma patients treated with curative intent. J Hepatol 2016;64:978-9. [PMID: 26723897 DOI: 10.1016/j.jhep.2015.12.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
121 Huo TI, Liu PH, Hsu CY. ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Is It Sufficient? Liver Cancer 2017;6:375-6. [PMID: 29234640 DOI: 10.1159/000481211] [Reference Citation Analysis]
122 Vitale A, Farinati F, Noaro G, Burra P, Pawlik TM, Bucci L, Giannini EG, Faggiano C, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Colecchia A, Fornari F, Marignani M, Vicari S, Bortolini E, Cozzolongo R, Grasso A, Aliberti C, Bernardi M, Frigo AC, Borzio M, Trevisani F, Cillo U; Italian Liver Cancer (ITA.LI.CA) group. Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. Hepatology 2018;68:1232-44. [PMID: 30048016 DOI: 10.1002/hep.30185] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
123 Liu PH, Hsu CY, Su CW, Huang YH, Hou MC, Rich NE, Fujiwara N, Hoshida Y, Singal AG, Huo TI. Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver Int 2020;40:2522-34. [PMID: 32511831 DOI: 10.1111/liv.14560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
124 Sun J, Yu X, Wang C, Yu C, Li Z, Nie W, Xu X, Miao X, Jin X. RIP-1/c-FLIPL Induce Hepatic Cancer Cell Apoptosis Through Regulating Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). Med Sci Monit 2017;23:1190-9. [PMID: 28270653 DOI: 10.12659/msm.899727] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
125 Che YQ, Zhang Y, Li HB, Shen D, Cui W. Serum KLKB1 as a Potential Prognostic Biomarker for Hepatocellular Carcinoma Based on Data-Independent Acquisition and Parallel Reaction Monitoring. J Hepatocell Carcinoma 2021;8:1241-52. [PMID: 34676182 DOI: 10.2147/JHC.S325629] [Reference Citation Analysis]
126 Tian MX, Liu WR, Wang H, Zhou YF, Jin L, Jiang XF, Tao CY, Tang Z, Zhou PY, Fang Y, Qu WF, Ding ZB, Peng YF, Dai Z, Qiu SJ, Zhou J, Lau WY, Fan J, Shi YH. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. BMC Med 2019;17:106. [PMID: 31164128 DOI: 10.1186/s12916-019-1341-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
127 Li GJ, Ji JJ, Yang F, Xu HW, Bai Y. Preoperative lymphocyte-to-monocyte ratio predicts survival in primary hepatitis B virus-positive hepatocellular carcinoma after curative resection. Onco Targets Ther 2017;10:1181-9. [PMID: 28260933 DOI: 10.2147/OTT.S110411] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
128 Sun C, Huang S, Ju W, Hou Y, Wang Z, Liu Y, Wu L, He X. Elevated DSN1 expression is associated with poor survival in patients with hepatocellular carcinoma. Hum Pathol 2018;81:113-20. [PMID: 30136646 DOI: 10.1016/j.humpath.2018.06.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
129 Li Z, Liang L, Duan W, Zhou C, Yang JJ. Non-linear relationship of gamma-glutamyl transpeptidase to lymphocyte count ratio with the recurrence of hepatocellular carcinoma with staging I-II: a retrospective cohort study. Infect Agent Cancer 2022;17:16. [PMID: 35395799 DOI: 10.1186/s13027-022-00428-0] [Reference Citation Analysis]
130 Wallace MC, Knuiman M, Huang Y, Garas G, Adams LA, MacQuillan G, Preen DB, Jeffrey GP. The Prognostic Ability of Major Hepatocellular Carcinoma Staging Systems Is Improved by Including a Treatment Variable. Dig Dis Sci 2018;63:2277-84. [PMID: 29808245 DOI: 10.1007/s10620-018-5132-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
131 Cai XR, Chen ZH, Liu MM, Lin JX, Zhang XP, Chen J, Lin Q, Ma XK, Wen JY, Xie SD, Wu XY, Dong M. Modified CLIP score with the albumin-bilirubin grade retains prognostic value in HBV-related hepatocellular carcinoma patients treated with trans-catheter arterial chemoembolization therapy. J Cancer. 2018;9:2380-2388. [PMID: 30026834 DOI: 10.7150/jca.22925] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
132 Demirtas CO, Ricco G, Ozdogan OC, Baltacioglu F, Ones T, Yumuk PF, Dulundu E, Uzun S, Colombatto P, Oliveri F, Brunetto MR, Gunduz F. Proposal and Validation of a Novel Scoring System for Hepatocellular Carcinomas Beyond Curability Borders. Hepatol Commun 2021. [PMID: 34751001 DOI: 10.1002/hep4.1836] [Reference Citation Analysis]
133 Alkhalili E, Greenbaum A, Luo L, Rodriguez R, Caldwell K, Estrada OM, O'Neill J, Nir I, Morris KT. Viral hepatitis status does not affect survival in patients with hepatocellular carcinoma. Ann Gastroenterol 2017;30:101-5. [PMID: 28042245 DOI: 10.20524/aog.2016.0097] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
134 Peng Y, Leng W, Duan S, Hong M. Long noncoding RNA BLACAT1 is overexpressed in hepatocellular carcinoma and its downregulation suppressed cancer cell development through endogenously competing against hsa-miR-485-5p. Biomed Pharmacother 2019;116:109027. [PMID: 31174090 DOI: 10.1016/j.biopha.2019.109027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
135 Adhoute X, Pénaranda G, Raoul JL, Bollon E, Pol B, Letreut YP, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Hardwigsen J, Lefolgoc G, Castellani P, Bronowicki JP, Bourlière M. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization. Eur J Gastroenterol Hepatol 2017;29:706-15. [PMID: 28195873 DOI: 10.1097/MEG.0000000000000852] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
136 Liao Y, Wei R, Yao R, Qin L, Li J, Yu J, Liao W. AGLR is a novel index for the prognosis of hepatocellular carcinoma patients: a retrospective study. BMC Surg 2021;21:72. [PMID: 33536005 DOI: 10.1186/s12893-020-01037-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Zhang H, Zhou Y, Li Y, Qin W, Zi Y, Liu Y, Qiu X, Xu H, Liao W, Huang Z. Predictive value of gamma-glutamyl transpeptidase to lymphocyte count ratio in hepatocellular carcinoma patients with microvascular invasion. BMC Cancer 2020;20:132. [PMID: 32070301 DOI: 10.1186/s12885-020-6628-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
138 Lu WP, Tang HW, Yang ZY, Jiang K, Chen YL, Lu SC. A proposed modification for the Barcelona Clinic Liver Cancer staging system: Adding bile duct tumor thrombus status in patients with hepatocellular carcinoma. Am J Surg 2020;220:965-71. [PMID: 32336518 DOI: 10.1016/j.amjsurg.2020.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
139 Liu Y, Cheng C, Zhou H, Hu S, Wang H, Xie Q, Lei L, Wang P, Liu G, Hu H. Comparison of Modified Child-pugh (MCP), Albumin-bilirubin (ALBI), and Child-pugh (CP) score for predicting of survival in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization. Bull Cancer 2021:S0007-4551(21)00241-1. [PMID: 34247763 DOI: 10.1016/j.bulcan.2021.04.017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Clark P. Serum markers for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2016;8:29-33. [PMID: 31041059 DOI: 10.1002/cld.565] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
141 Zhang F, Xue M, Jiang X, Yu H, Qiu Y, Yu J, Yang F, Bao Z. Identifying SLC27A5 as a potential prognostic marker of hepatocellular carcinoma by weighted gene co-expression network analysis and in vitro assays. Cancer Cell Int 2021;21:174. [PMID: 33731144 DOI: 10.1186/s12935-021-01871-6] [Reference Citation Analysis]
142 Chan AWH, Chong CCN, Mo FKF, Wong J, Yeo W, Johnson PJ, Yu S, Lai PBS, Chan ATC, To K, Chan SL. Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma: Albumin-bilirubin-based Italian staging. Journal of Gastroenterology and Hepatology 2017;32:221-8. [DOI: 10.1111/jgh.13457] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
143 Jeng LB, Li TC, Hsu SC, Teng CF. Association of Increased Programmed Death Ligand 1 Expression and Regulatory T Cells Infiltration with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection. Viruses 2022;14:1346. [PMID: 35746817 DOI: 10.3390/v14061346] [Reference Citation Analysis]
144 Vitale A, Farinati F, Finotti M, Di Renzo C, Brancaccio G, Piscaglia F, Cabibbo G, Caturelli E, Missale G, Marra F, Sacco R, Giannini EG, Trevisani F, Cillo U, Associazione Italiana Per Lo Studio Del Fegato Aisf Hcc Special Interest Group, Italian Liver Cancer Ita Li Ca Study Group. Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications. Cancers (Basel) 2021;13:1673. [PMID: 33918125 DOI: 10.3390/cancers13071673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]